Loading...
Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
25 Aug 25
Updated
25 Aug 25
AnalystLowTarget's Fair Value
CHF 37.09
34.6% overvalued intrinsic discount25 Aug
CHF 49.92
1Y
32.4%7D
2.1%1Y
32.4%7D
2.1%